Maxim Group Reaffirms Their Buy Rating on Beyondspring Inc

In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on Beyondspring Inc (NASDAQ: BYSI), with a price target of $48. The company’s shares opened today at $26.78.

McCarthy wrote:

“We maintain our Buy rating on BeyondSpring (BYSI), though lower our price target to $48, from $52, following the release of 1Q18 (March) results.”

According to TipRanks.com, McCarthy is a 4-star analyst with an average return of 10.4% and a 42.9% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, SELLAS Life Sciences Group Inc, and ContraVir Pharmaceuticals Inc.

Currently, the analyst consensus on Beyondspring Inc is Moderate Buy and the average price target is $54, representing a 101.6% upside.

In a report issued on June 19, H.C. Wainwright also reiterated a Buy rating on the stock with a $60 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $48.49 and a one-year low of $19.55. Currently, Beyondspring Inc has an average volume of 12.61K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BeyondSpring, Inc. is a clinical stage company, which engages in the development of cancer therapies. It focuses on non-small cell lung cancer, neutropenia prevention, and plinabulin and nivolumab. The company was founded by Lan Huang and Lin Qing Jia in 2013 and is headquartered in New York, NY.